logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9409909 B1

PDFFull Text
Date of Patent:
Aug. 09, 2016

Filed:

Jul. 29, 2014

N-(2-(hetaryl)aryl)arylsulfonamides and n-(2-(hetaryl)hetaryl)arylsulfonamides

Applicant:

Chemocentryx, Inc., Mountain View, CA (US);

Inventors:

Trevor T. Charvat, San Jose, CA (US);

Cheng Hu, Menlo Park, CA (US);

Anita Melikian, San Francisco, CA (US);

Aaron Novack, San Jose, CA (US);

Andrew M. K. Pennell, San Francisco, CA (US);

Edward J. Sullivan, San Jose, CA (US);

William D. Thomas, San Jose, CA (US);

Solomon Ungashe, Fremont, CA (US);

Penglie Zhang, Foster City, CA (US);

Jay Powers, Pacific, CA (US);

Sreenivas Punna, Sunnyvale, CA (US);

Assignee:

ChemoCentryx, Inc., Mountain View, CA (US);

Attorneys:

Brinks Gilson & Lione

Ryan L. Marshall

Primary Examiner:

Niloofar Rahmani

Int. Cl.
CPC ...
C07D 213/02 (2006.01); C07D 473/00 (2006.01); C07D 209/08 (2006.01); C07D 231/12 (2006.01); C07D 231/14 (2006.01); C07D 231/16 (2006.01); C07D 231/56 (2006.01); C07D 233/61 (2006.01); C07D 235/06 (2006.01); C07D 235/08 (2006.01); C07D 249/06 (2006.01); C07D 249/18 (2006.01); C07D 401/04 (2006.01); C07D 401/14 (2006.01); C07D 403/06 (2006.01); C07D 413/04 (2006.01); C07D 413/14 (2006.01); C07D 417/04 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01); A61K 31/404 (2006.01); A61K 31/415 (2006.01); A61K 31/4164 (2006.01); A61K 31/4192 (2006.01); A61K 31/437 (2006.01); A61K 31/496 (2006.01); A61K 31/52 (2006.01); A61K 31/5377 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
C07D 473/00 (2013.01); A61K 31/404 (2013.01); A61K 31/415 (2013.01); A61K 31/4164 (2013.01); A61K 31/4192 (2013.01); A61K 31/437 (2013.01); A61K 31/496 (2013.01); A61K 31/52 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); C07D 209/08 (2013.01); C07D 231/12 (2013.01); C07D 231/14 (2013.01); C07D 231/16 (2013.01); C07D 231/56 (2013.01); C07D 233/61 (2013.01); C07D 235/06 (2013.01); C07D 235/08 (2013.01); C07D 249/06 (2013.01); C07D 249/18 (2013.01); C07D 401/04 (2013.01); C07D 401/14 (2013.01); C07D 403/06 (2013.01); C07D 413/04 (2013.01); C07D 413/14 (2013.01); C07D 417/04 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01); C12N 2501/999 (2013.01);
Abstract

Compounds are provided that act as potent antagonists of the CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.

Find Patent Forward Citations

Loading…